[ad_1]
AstraZeneca has said that there is “no evidence” that its vaccine increases the risk of blood clots.
Use of the jab was temporarily suspended in Ireland after concerns were raised about severe blood clots in several patients receiving the treatment in Norway.
In a statement issued tonight, the company said 15 deep vein thrombosis events and 22 pulmonary embolism events have been reported among those who received the vaccine as of March 8.
The company has carried out a review of all available safety data on more than 17 million vaccinated people in the European Union and the United Kingdom.
They added that this is much less than the amount that would be expected to occur naturally in a general population of this size and is similar in other licensed COVID-19 vaccines.
Medical Director Ann Taylor said: “Around 17 million people in the EU and UK have received our vaccine and the number of blood clot cases reported in this group is less than the hundreds of cases that would be expected. among the general population.
“The nature of the pandemic has led to increased attention in individual cases and we go beyond standard practices for monitoring the safety of authorized drugs when reporting vaccine events, to ensure public safety.”
The statement said there have been no confirmed problems related to any batch of the vaccine used in Europe or the rest of the world.
He added: “The additional tests have been and are being carried out independently by ourselves and the European health authorities and none of these new tests have proven to be a cause for concern.
“During the production of the vaccine, AstraZeneca, its partners and more than 20 independent testing laboratories perform more than 60 quality tests.
“All tests must meet strict quality control criteria and this data is sent to regulators in each country or region for independent review before any lot can be shipped to countries.”
The company said it will continue to keep the issue under “close review” and urged people to get vaccinated when invited to do so.
[ad_2]